Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells

Ferrao, P T, Bukczynska, E P, Johnstone, R W, McArthur, G A·2012·Oncogene
DOI 10.1038/onc.2011.358

Cited by (134)

Items 101–134 of 134

  1. Establishment of a primary renal lymphoma model and its clinical relevance
    Xiaoxi Li, Minyao Deng, Chenxiao Zhang, Lingli Luo, Hui Qian · 2023 · Frontiers in Oncology
  2. Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma
    Enrico Derenzini, Ilaria Iacobucci, Claudio Agostinelli, Enrica Imbrogno, Clelia Tiziana Storlazzi, Alberto L’Abbate, Beatrice Casadei, Anna Ferrari, Andrea Ghelli Luserna di Rorà, Giovanni Martinelli et al. · 2015 · Experimental Hematology and Oncology
  3. Preclinical Profiles and Contexts for CHK1 and CHK2 Inhibitors
    Ian Collins, Michelle Dawn Garrett · 2018 · Cancer drug discovery and develogment/Cancer drug discovery and development
  4. Tumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity
    Andrew J. Massey · 2016 · Scientific Reports
  5. Inhibition of DNA Repair as a Therapeutic Target
    Stephany Jane Veuger, Nicola J. Curtin · 2014 · Elsevier eBooks
  6. The DNA Damage Response: Roles in Cancer Etiology and Treatment
    Laura R. Butler, Oren Gilad, Eric J. Brown · 2018 · Cancer drug discovery and develogment/Cancer drug discovery and development
  7. Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma
    Yanguo Kong, Gustavo A. Barisone, Ranjit S. Sidhu, Robert T. OʼDonnell, Joseph M. Tuscano · 2015 · Molecular Medicine
  8. The “extreme phenotype approach” applied to male breast cancer allows the identification of rare variants of ATR as potential breast cancer susceptibility alleles
    Martin Chevarin, Diana Alcantara, Juliette Albuisson, Marie‐Agnès Collonge‐Rame, Céline Populaire, Zohair Selmani, Amandine Baurand, Caroline Sawka, Geoffrey Bertolone, Patrick Callier et al. · 2023 · Oncotarget
  9. MYC oncogenes as potential anticancer targets
    Radostina Alexandrova, Črtomir Podlipnik · 2023 · Elsevier eBooks
  10. Targeting DNA Repair Pathways for Cancer Therapy
    Conchita Vens, Robert William Sobol · 2012 · Springer eBooks
  11. Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling
    Alina Batzilla, Junyan Lu, Jarno L. Kivioja, Kerstin Putzker, Joe Lewis, Thorsten Zenz, Wolfgang K. Huber · 2022 · PLoS Computational Biology
  12. Pharmacoinformatics-based prediction of Checkpoint kinase-1 inhibitors from Momordica charantia Linn. for cancer
    Subramanian Haripriya, Muniyandi Vijayalakshmi, Ala Chandu, Sankaranarayanan Murugesan, Parasuraman Pavadai, Selvaraj Kunjiappan, Sureshbabu Ram Kumar Pandian · 2024 · Computational Biology and Chemistry
  13. DNA Repair and Chemotherapy
    Seiya Sato, Hiroaki Itamochi · 2015 · InTech eBooks
  14. Targeting DNA Damage Response Pathways in Cancer
    Ganiy Opeyemi Abdulrahman, Nicola J. Curtin · 2017 · Elsevier eBooks
  15. Targeting TP53 to augment therapeutic response in head and neck cancer
    Abdullah A. Osman, Antje Lindemann, Li Wang, Steven Jay Frank, Jeffrey N. Myers · 2020 · Elsevier eBooks
  16. The Inhibition of DNA Damage Response Contributes to Cancer Radiotherapy
    Meng Sun, Yaxiong Chen, Burong Hu · 2018 · International Journal of Radiology
  17. Investigations of the novel checkpoint kinase 1 inhibitor SRA737 in non-small cell lung cancer and colorectal cancer cells of differing tumour protein 53 gene status
    Ali JN Duabil, Christian R. Cooper, Esraa Aldujaily, Sarah E. R. Halford, Sandra Hirschberg, Sidath D. KATUGAMPOLA, George D.D. Jones · 2023 · Exploration of Targeted Anti-tumor Therapy
  18. Targeting CHK1 for Cancer Therapy: Rationale, Progress and Prospects
    David A. Gillespie · 2018 · Cancer drug discovery and develogment/Cancer drug discovery and development
  19. Check’-ing DLBCL
    Itziar Salaverría, Sı́lvia Beà · 2015 · Oncoscience
  20. ATR as a Therapeutic Target
    Fiona K. Middleton, Nicola J. Curtin · 2012 · Springer eBooks
  21. Role of checkpoint kinase 1 in malignant melanoma
    Joanne Smith · 2013 · Enlighten: Theses (The University of Glasgow)
  22. Short-circuiting the cell cycle for cancer therapy
    David A. Gillespie · 2012 · Cell Cycle
  23. Selective targeting of cancer cells through inhibition of Checkpoint kinase 1
    Grete Hasvold · 2012 · NORA - Norwegian Open Research Archives
  24. Using genetics to identify epigenetic and signal transduction targets in cancer
    Joydeep Bhadury · 2016 · Gothenburg University Publications Electronic Archive (Gothenburg University)
  25. Biomarkers for Early Detection of Familial Breast Cancer
    Burak Yılmaz, Catherine A. Moroski-Erkul, Ömer Faruk Hatipoğlu, Esra Gündüz, Debmalya Barh, Mehmet Gündüz · 2015 · CRC Press eBooks
  26. An evaluation of the checkpoint kinase inhibitor V158411
    Peter Stephens · 2015
  27. Immunohistochemical Targeting of p110β Isoform of phosphatidylinositol 3-kinase co-associated with Cyclin-Dependent Kinase 1 in a Group of Tissues from Iraqi Patients with Breast Cancer
    Mohammed A.M. Al-Qurtas · 2019 · AL-Kindy College Medical Journal
  28. Exploiting genomic instability as an Achilles’ heel in cancer
    Sergi Guerrero Llobet · 2021
  29. Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High‐Risk Diffuse Large B Cell Lymphoma
    Sara Ovejero, J. Devin, L. Alibert, Camille Soun, Yea-Lih Lin, Laure Dutrieux, M. Abouladzé, Elvira Garcia de Paco, Ouissem Karmous Gadacha, Angelos Constantinou et al. · 2025 · Hematological Oncology
  30. Targeting DNA damage response pathways in cancer
    Carlos Torrado, Harold Nathan Tan, Timothy Anthony Yap · 2026 · Elsevier eBooks
  31. Contribution à l’étude des mécanismes de sensibilité aux traitements antiandrogènes dans les cancers du sein moléculaires apocrines
    Thomas Grellety · 2018
  32. Plasticity of Non-Apoptotic Residual Tumor Cells After Neoadjuvant Immunochemotherapy: Epigenetic and Microenvironmental Determinants
    Wenjun Meng, R Li, Peiliang Xie, Bangyi Xiang, Qing Li · 2026 · Biomolecules
  33. BindingDB Entry 50045098: Development of synthetic lethality anticancer therapeutics.
    BindingDB · 2016 · UC San Diego
  34. BindingDB Entry 50022526: The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
    BindingDB · 2025 · UC San Diego